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6INTRODUCTION AND TOPIC MOTIVATION 
Chemical Pathology, Diabetes Mellitus and the Former Transkei
I am a Chemical Pathologist by training. The term ‘pathology’ derives from the Greek words “pathos” 
meaning	“disease”	and	“logos”	meaning	“a	treatise”.	Pathology	is	a	major	field	of	Medicine	that	deals	
with the essential nature of diseases, their processes and consequences.  A medical doctor that 
specializes in pathology is known as ‘a pathologist’. Chemical Pathology is that branch of Pathology, 
which deals specially with the biochemical basis of diseases and the use of biochemical tests carried 
out	at	hospital	laboratories	on	the	blood	and	other	body	fluids	to	provide	support	to	clinicians.	It	
does this in the following processes:
Screening: identifying an unrecognised disease in individuals without signs or symptoms 
Diagnosis: identifying the nature and cause of a disease
Prognosis: predicting the probable outcome or course of a disease
Management: implementing health interventions to deal with a disease 
Along	these	lines,	chemical	pathologists	have	two	main	clinical	roles.	The	first	one	is	to	collaborate	
with healthcare professionals such as clinicians and nurses, to advise them on how to choose the 
tests and how to interpret their results when investigating a case.  The second role is a personal 
responsibility for patients in outpatient clinics and on the hospital wards, which entails validation 
and interpretation of test results, mostly for peculiarly surprising results and for infrequent or highly 
specialised tests. 
In	addition,	the	roles	of	an	academic	pathologist	include	devising	and	conducting	scientific	research	
and training healthcare personnel.
Chemical pathology investigations are of value, to different extents, in recognition of most diseases. 
However, the importance and relevance is essential in those conditions in which biochemical 
derangements constitute the essential nature of the disease; for example, hepatic, renal and endocrine 
diseases such diabetes mellitus. Diabetes is a common chronic disease worldwide that starts as 
an abnormal blood glucose level associated with a series of related biochemical abnormalities. In 
addition, a whole assortment of biochemical investigations provides evidence for a wide range of 
severe acute and long-term diabetic complications. Abnormal tests results from diabetic patients, 
are not only frequent but also, quite commonly, are serious enough to require attention by the 
chemical pathologists in conjunction with clinical staff.   
Under the above circumstances, the subject of “diabetes mellitus” has also attracted my interest 
as a researcher with the subsequent engagement in some interdepartmental collaborative research 
projects on diabetes.  These are the reasons informing my choice of diabetes mellitus as a topic for 
this presentation.  
Lastly,	due	to	my	many	years	of	affiliation	to	the	University	of	Transkei,	legacy	institution	of	the	Walter	
Sisulu University, and, in consonance with the principle of community relevance of this academic 
institution, most of our research on diabetes mellitus has addressed epidemiological issues. The 
goal has been to contribute to develop the knowledge and understanding of the epidemiological 
patterns, clinical and biochemical peculiarities inherent to diabetes mellitus in the community of the 
former Transkei; a largely rural and historically disadvantaged population sector of the Eastern Cape, 
predominantly constituted by black South Africans of Xhosa ethnic origin. Those are the reasons for 
combining the topic of diabetes with the community of the former Transkei.
In	spite	of	the	advances	in	the	medico-pharmaceutical	field,	and	the	efforts	made	by	governments	and	
non-governmental organizations, the prevalence of diabetes mellitus has been increasing worldwide 
7at an alarming rate in the last few decades. The geographic pattern of this epidemic across the globe 
is	quite	uneven.		However,	some	significant	differences	recently	identified	embody	the	distinctive	
characteristics of the different continents, regions, countries, provinces and communities. 
Understanding	the	reasons	behind	this	epidemic	 is	essential	 for	 the	 identification	of	specific	and	
effective strategic actions required. Combinations of different factors contribute to the global burden 
of	diabetes.	Although	this	multi-factorial	influence	is	in	general,	not	arguable,	it	is	widely	accepted	
that the geographic differences observed result from the varying degrees of intensity of each of 
its regulatory factors. Thus, it is not likely that a single strategy could be a practical solution of 
the	global	problem.	A	locally	relevant	approach	is	required	for	each	different	area.	The	first	step	
in this process is the delimitation of the differences and commonalities between adjacent areas or 
coexisting populations.
This lecture intends to raise awareness on the current global epidemic of diabetes mellitus, its 
increasing prevalence and growing burden, as well as its socio-economic and healthcare impact. It 
also intended to describe the pattern of diabetes observed in the community of the former Transkei. 
It is also the intention to highlight possible collaborative areas to counteract the increasing burden 
of	diabetes	in	South	Africa	and	more	specifically	in	the	community	around	WSU.	
 
DIABETES MELLITUS 
Definition 
According	to	the	World	Health	Organization	(WHO),	“diabetes	mellitus	(DM)	is	a	metabolic	disorder	
characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein 
metabolism	 resulting	 from	 defects	 in	 insulin	 secretion,	 insulin	 action,	 or	 both”	 (World	 Health	
Organization	1999).
Historical background 
There are evidences that diabetes mellitus, as a disease, has been described since around 1500 B.C. 
in the ancient Egypt as a condition associated with excessive urination and loss of weight. Although 
most civilizations have in some way referred to the disease, it was the Greek physician Aretaeus 
around	the	80	to	138	B.C.,	who	introduced	for	the	first	time	the	term	“diabetes”,	whilst	 later;	 in	
the 18th century;	the	Scottish	physician	John	Rollo	introduced	the	adjective	“mellitus”	to	reflect	the	
“honeyed”	aspect	of	the	diabetics’	urine.	It	was	only	in	1776	that	Matthew	Dobson	identified	the	
increased level of glucose in the urine of diabetics and almost 150 years later a group of scientists 
discovered the insulin, a pancreatic hormone controlling the blood glucose. Since then, the perception 
and management of diabetes mellitus has changed dramatically as well as the life expectancy of 
diabetic patients. An important number of other scientists have continued the arduous work in the 
last	century	contributing	to	the	current	knowledge	on	this	condition	(Holt,	Cockram	2010;	Flyvbjerg	
&	Goldstein,	2010,	Chapter	1,	p.	3-9).	
Diabetes	mellitus	belongs	to	the	group	of	non-communicable	diseases	(NCDs).	This	category	includes	
non-infectious conditions characterized by long duration and a generally slow progression.  Appart 
from diabetes the other three most common non-communicable diseases currently affecting the 
world	are	cardiovascular	diseases	(such	as	heart	attack	and	stroke);	cancers,	and	chronic	respiratory	
diseases	(such	as	chronic	obstructed	pulmonary	disease,	asthma).
Non-communicable diseases are largely more frequent in the low- and middle-income countries 
where nearly 80% of NCD worldwide deaths occur. They are the leading causes of death in all regions 
8except	Africa,	where	common	causes	of	death	are	those	related	to	communicable	(infectious)	and	
nutritional diseases together with maternal and foetal deaths. However, projected estimates suggest 
that,	by	2030,	the	mortality	attributable	to	NCDs	in	Africa,	will	most	likely	exceed	the	current	leading	
causes	of	death	(World	Health	Organization	2011).	
CLASSIFICATION OF DIABETES MELLITUS
According	to	the	classification	by	the	American	Diabetes	Association	(2013a)	and	the	World	Health	
Organization	(Expert	Committee	on	the	Diagnosis	and	Classification	of	Diabetes	Mellitus,	2003)	four	
main types of diabetes mellitus are recognized, namely:
Type 1 DM,	previously	known	as	juvenile	or	insulin	dependent	DM	(IDDM),	which	usually	presents	
before the age of 35 years. This type, although more clinically devastating, accounts only for about 
5% to 10% of the global number of diabetics. It is associated with strong genetic predisposition to 
the autoimmune destruction of the pancreatic beta cells. The progression of the beta cell destruction, 
which	 is	usually	more	rapid	for	 infants	and	children	than	for	adults,	results	 in	 insufficient	 insulin	
production	by	 the	endocrine	pancreas.	The	deficiency	of	 insulin	makes	 these	diabetics	prone	 to	
ketoacidosis thus; becoming dependent on insulin therapy to survive.
Type 2 DM,	previously	named	as	diabetes	of	 the	adult	or	non-insulin	dependent	DM	(NIDDM),	
which presents commonly in subjects older than 35 years. This type is frequently associated with 
obesity,	mostly	of	the	central	type	(abdominal).	The	disease	mechanism	is	related	to	deficient	insulin	
action	(or	“insulin	resistance”),	rather	than	to	the	insulin	amount.	Initially	the	hyperglycaemia	is	not	
so severe, thus, asymptomatic. It often remains undiagnosed for many years, progressing gradually, 
until becoming clinically overt. Ketoacidosis is not common with this type. Although, this type is 
sometimes treated with insulin, these patients usually respond to oral drugs that enhance the insulin 
action.	Type	2	DM	accounts	for	the	vast	majority	of	cases	worldwide	being	the	one	responsible	for	
the current global diabetes epidemic.
Other specific types:	 these	 are	 relatively	 rare	 and	 usually	 associated	with	 specific	 genetic	 or	
endocrine conditions. The mechanism of disease entails a variety of complex processes such as 
endocrine dysregulations usually not primarily pancreatic, genetic defects related to the pancreatic 
beta cells or to the insulin action. Others are due to diseases of the exocrine pancreas, chemicals, 
and to some viral infections. 
Gestational DM:	 includes	 different	 degrees	 of	 glucose	 intolerance,	 which	 appear	 for	 the	 first	
time during pregnancy. The mechanism of the disease involves some complex endocrine changes 
associated with pregnancy.
The	main	advantage	of	using	a	classification,	 in	 the	medical	context,	 is	 to	separate	groups	 that	
share common mechanisms, clinical presentations, investigations and thus a common therapeutic 
approach.	Therefore,	it	is	not	surprising	that	when	a	subgroup,	within	a	specific	type,	requires	specific	
variation	of	the	traditional	therapeutic	approach,	it	is	identified	as	a	subtype.	Some	subtypes	of	type	
1	and	type	2	DM	have	also	been	described	to	highlight	their	need	for	special	therapeutic	approach	
at	least	under	certain	circumstances	(American	Diabetes	Association	2013a;	Balasubramanyam	et	
al	2008).
9DIAGNOSIS OF DIABETES MELLITUS 
Although there is a classical combination of clinical signs and symptoms usually accompanying 
hyperglycaemia such as polyuria, polydipsia, weight loss, sometimes with polyphagia, and blurred 
vision	 the	 clinical	 presentation	 lacks	 sensitivity	 and	 specificity	 for	 the	 confirmation	 of	 diabetes	
mellitus.	Therefore,	the	diagnosis	of	DM	has	been	set	to	specific	“biochemical	criteria”	based	on	
the	levels	of	blood	glucose	in	either	the	fasting	state	or	2	hours	after	the	oral	administration	of	a	
standardized	glucose	load	(glucose	tolerance	test).
(National	 Diabetes	 Data	 Group,	 1979;	 Expert	 Committee	 on	 the	 Diagnosis	 and	 Classification	 of	
Diabetes	Mellitus	1997)
In	the	last	few	decades,	the	biochemical	criteria	for	diagnosing	DM	have	been	revised	and	modified	
as a consequence of new concrete evidences regarding the expression of the disease and its 
complications in relation to the level of hyperglycaemia. Table 1 shows a summary of those changes 
as	published	by	Herman	et	al	(2005).
 
Table 1: Comparison of the different biochemical criteria for diagnosis of diabetes 
mellitus in the last five decades 
Changes in diagnostic criteria along the years have also brought some implications to the total 
prevalence of diabetes mellitus reported in the independent research publications. Thus, it is 
established that to provide comparable prevalences at different points in time, the original data 
requires some adjustments to match the criteria used. Similar effects arise when different diagnostic 
criteria	are	used	to	obtain	estimates	of	DM	prevalence	(Shaw	et	al	1999).	
Currently there are two approaches to the biochemical diagnosis of DM. First, the American Diabetes 
Association	 (ADA)	 (American	Diabetes	Association	2013a)	has	agreed	on	using	only	 the	plasma	
glucose	 levels	during	a	 fasting	state.	On	 the	other	hand,	 the	World	Health	Organization	 (WHO)	
accepts the same fasting plasma glucose criteria but recommends, in addition, the use of the level of 
plasma glucose in the second hour of the glucose tolerance test. This additional biochemical criterion 
increases the sensitivity of the biochemical diagnosis as some differences in the fasting and the 
post-load	glucose	values	are	commonly	present	in	different	populations.	Thus,	if	the	2-hour	plasma	
glucose is not measured, the patient’s glucose-regulation status is “uncertain” because diabetes or 
impaired	glucose	tolerance	(IGT)	cannot	be	excluded	(World	Health	Organization	2006).
For	both,	the	ADA	and	the	WHO	diagnostic	recommendations,	the	cut-off	values	for	diabetes	are	
fasting	plasma	glucose	≥	7.0mmol/L	and	the	2–hours	OGTT	plasma	glucose	≥	11.1	mmol/L.	The	
clinical	value	of	these	biochemical	criteria	is	only	to	confirm	the	diagnosis	of	diabetes.	Thus,	they	
apply	uniformly	to	the	diagnosis	of	type	1,	type	2	and	non-specific	types	of	DM.		In	the	case	of	
“gestational	 diabetes	mellitus”	 (GDM),	 due	 to	 the	 special	 implications	 of	 hyperglycaemia	 during	
Fajans and Conn
(1954)(ref.1)
USPHS
(1964)(ref.11)
NDDG
(1979)(ref.3)
WHO
(1980/1985)(ref.27)
ADA
(1997)(ref.4)
Glucose dose 1.75g/kg IBW* 100g 75g 75g 75g
Fasting - 125 140 140 127
30 min - - 200 - -
60 min 185 195 200 - -
90 min 160 - 200 - -
120 min 140 140 200 - 200
180 min - 125 - 200 -
Criteria for
positive test
All three At least three Fasting or 120min 
and intermediate
Fasting or 120min Fasting or 120min
ADA, American Diabetes  Association, NDDG National Diabetes Data Group, USPHS Us Public Health Service, WHO World Health Organization, IBW ideal body weight from Metropolitan Life 
Insurance Tables
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pregnancy, the biochemical criteria require higher sensitivity, therefore, the recommended levels are 
lower	than	for	other	types	of	diabetes	(American	Diabetes	Association	2012).
Following	biochemical	diagnosis,	the	type	of	diabetes	is	identified	depending	on	the	evidence	collected	
for each patient with respect to the family history of DM, the age at the onset, the presence of 
specific	risk	factors	and	the	clinical	course	of	the	disease	among	others	(World	Health	Organization	
2006).	
 
In	terms	of	diagnosis,	there	are	some	fairly	recent	studies	(ADA	2009;	Nathan	et	al	2008)	showing	
evidence	in	support	of	using	the	glycosylated	Haemoglobin	(HbA1c),	a	test	that	correlates	with	the	
long-term	presence	of	hyperglycaemia,	to	confirm	diabetes.	Because	of	 irregularities	 in	technical	
standardization	of	 the	test,	 in	2011	the	World	Health	Organization	 introduced	 it	as	a	conditional	
recommendation. A cut off value of HbA1c > 6.5% is diagnostic of diabetes “providing that stringent 
quality assurance tests are in place, and assays are standardised to the international reference 
values, and there are no conditions present which preclude its accurate measurement”.  However, a 
value	of	less	than	6.5%	does	not	exclude	diabetes	(World	Health	Organization	2011).	
RISK FACTORS AND PREDISPOSING CONDITIONS FOR DIABETES
The risk factors for diabetes are related to the mechanism of disease, which are particularly different 
for each type of diabetes. In general, the risk factors are categorized under the two main groups of 
“modifiable”	and	“non-modifiable”	according	to	the	possibility	of	using	interventions	to	control	their	
expression.
RISK FACTORS FOR TYPE 1 DM
In	 the	 case	 of	 type	 1	 diabetes	 mellitus,	 the	 disease	 is	 associated	 with	 non-modifiable	 genetic	
and immunological factors. There is a genetic predisposition arising from the makeup of the HLA 
susceptibility	loci,	particularly	for	HLA-DR3,	HLA	DR4	and	their	combinations	(Ekoe	et	al	2008;	Osei	
et	al	2003).	
Some	 studies	 have	 reported	 additional	 details	 regarding	 allele-specific	 probes	 used	 in	 different	
populations	 from	 sub-Saharan	Africa	 have	 found	 a	 positive	 association	 of	 diabetes	with	 specific	
genetic	markers	such	as	the	alleles	DQB*0201,	DQB*0302,	DRB*0301,	and	DRB*0401	and	negative	
association	with	DQB*0501	(Mbanya	et	al	2001).	In	addition,	polymorphisms	of	the	toll-like	receptor	
3	(TLR3),	which	is	part	of	the	innate	immune	system,	has	been	reported	in	type	1	diabetics	from	
South	Africa	by	Pirie	and	co-workers	(2005).
RISK FACTORS FOR TYPE 2 DM
The	two	categories	of	risk	factors,	modifiable	and	non-modifiable,	are	important	for	type	2	DM.
Non-modifiable risk factors
These include the age, the family history and the ethnicity. 
The widespread observation is that the risk of becoming diabetic increases progressively with the 
age	reaching	peak	frequencies	around	the	65	years	(Levitt	2008;	International	Diabetes	Federation	
2011).	This	association	is	responsible	for	the	relatively	steady	high	prevalence	of	diabetes	in	the	
developed	countries	where	the	older	age	group	prevails	in	the	population	distribution	(Elbagir	et	al	
1996,	1998;	Amoah,	Owusu	&	Adjei	2002).	Given	this	fact,	it	is	also	understandable	that	most	new	
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cases in the projected prevalence of diabetes will emerge from the developing countries because of 
the ageing of the population inherent to socioeconomic development. 
The association with a positive family history of diabetes supports the stronger genetic predisposition 
of	type	2	diabetes	although	usually	by	mechanisms	other	than	autoimmunity.			The	family	history	of	
diabetes	has	also	been	widely	identified	as	an	independent	risk	factor	for	this	disease	(Permut	1990,	
Hitman	&	McCarthy	1991,	Klein	et	al	1996,	American	Diabetes	Association	2013a).	There	 is	also	
evidence	of	its	higher	influence	in	African	populations	(Elbagir	1996	&	1998,	Erasmus	et	al	2001a,	
Motala	et	al	2008)	although	according	to	Levitt	et	al	(1993)	this	pattern	has	not	been	supported	by	
studies in black South African urban communities.
MODIFIABLE RISK FACTORS
Modifiable	 risk	 factors	 include	 adiposity,	 physical	 activity,	 diet,	 associated	 diseases,	 as	 well	 as	
urbanization and migration.
Increased adiposity, expressed in the categories of overweight and obesity, is derived from 
anthropometric measurements. A commonly used indicator of adiposity is the Body Mass Index 
(BMI),	which	 results	 from	 a	mathematical	 calculation	 that	 combines	 the	weight	 and	 the	 height	
of the person. Increased BMI and other indicators of increased adiposity such as the waist to 
hip	 ratio	 (WHR)	and	 the	waist	 circumference	have	been	 frequently	observed	 in	association	with	
diabetes and other abnormal blood glucose states. Most studies have reported that the obesity of 
predominant central or abdominal distribution associates with higher risk of diabetes, as opposed to 
the	protective	role	attributed	to	one	predominant	around	hip	circumference	(Kissebah	&	Krakower	
1994;	Goedecke,	Jennings	&	Lambert	2005).	
Physical activity and the diet have also been attributed to some extent in increasing the risk of 
diabetes. Most published studies from Africa regarding physical activity do have limitations in the 
validity of the tool used for data collection. Two notable studies from Cameroon and Kenya based 
on standardized monitoring of physical activity in free-living persons have strongly supported the 
higher	level	of	physical	activity	present	in	rural	life	and	its	beneficial	effect	on	the	glucose	regulation	
(Christensen	2008;	Assah	2009).
A	review	on	the	effect	of	the	diet	on	the	risk	of	DM	published	by	Parillo	&	Riccardi	(2004)	found	that	
the	dietary	pattern	is	commonly	reportedreported	influencing	the	risk	of	type	2	DM.	Thus,	a	leading	
risk factor to be controlled is the diet and its effects on body weight. Most diabetes prevention 
programs	have	provided	evidence	of	the	benefits	of	changes	in	diet	behaviour	(Dehanty	&	Halford	
1993; American Diabetes Association and National Institute of Diabetes, Digestive and Kidney 
Diseases	2002).	Among	the	various	recommended	diet	modifications,	one	of	the	most	frequent	is	
the	reduction	in	type	and	total	intake	of	fats.	According	to	Storlien	et	al	(1996)	the	high	intake	of	fats	
is not only related to higher risk of weight gain, but it also induces increases of insulin sensitivity, 
which	are,	independent	on	changes	in	body	weight.	Several	studies	have	also	confirmed	the	role	of	
saturated	animal	fat	as	a	risk	factor	for	type	2	diabetes,	and	the	protective	effect	of	the	vegetable,	
unsaturated	fats.	(Laaksonen	et	al	2002;	Wang	et	al	2003).
The typical western diet has been associated with obesity. The introduction of western-like diet 
commonly associated with urbanization have also been reported to be associated with higher risk of 
diabetes not only in the white and Indian community but also especially in the black African people 
(Loock	et	al	2006).	In	the	African	context,	there	is	a	shortage	of	evidence-based	reports	on	physical	
activity	and	the	nutritional	assessment	mostly	due	to	the	technical	difficulties	in	obtaining	validated	
measurements	for	their	timelines	under	normal	living	conditions	(World	Health	Organization	1990;	
Fung	et	al	2007).	
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However, in black South Africans records show of increasing consumption of fat and decreasing intake 
of carbohydrates in both the rural and urban settings. Associated effects of physical activity and 
urbanization	are	somehow	moderating	the	influence	exerted	by	the	diet.	Urbanization,	a	condition	
commonly associated with migration of people, results in an increased availability of fruits and 
vegetables improving the nutrient content of urban diets whilst it could also increase the intake of 
fats	associated	with	the	“westernization”	of	the	diet	(Bourne,	Lambert	&	Steyn,	2002;	Mennen	et	al	
2001;	Vorster	et	al	2005).
Some studies have provided evidence that the changes in dietary pattern associated with the 
urbanization of black South African communities also increase their susceptibility, not only to diabetes, 
but	also	cardiovascular	diseases	in	general	(Steyn	et	al	2005;	Tibazarwa	et	al	2009).
Cultural influences related to increased risk for type 2 diabetes 
In the African environment,  the most common risk emerging from the cultural expressions is the 
misconception	related	to	the	popular	belief	that	obesity	reflects	gracious	living,	which	can	also	lead	
to	the	misperception	that	obesity	is	also	a	sign	of	excellent	health	(Goedecke,	Jennings	&	Lambert	
2005;	Renzaho	2004).	
Lastly, in terms of risks for diabetes, in the African context, there have been some reports supporting 
the	 association	 of	 antiretroviral	 therapy	 used	 for	 HIV/AIDS	with	 some	metabolic	 derangements	
including abnormal glucose regulation. The extent of this association as reported by different 
studies	fluctuates	between	2	and	14%	(Friis	et	al	2003;	Smith	et	al	2004;	Glass	et	al	2006;	Tien	et	
al	2007).
Biochemical categories of increased risk for diabetes 
In	 1997	 and	 2003,	 the	 Expert	 Committee	 on	 Diagnosis	 and	 Classification	 of	 Diabetes	 Mellitus	
recognized an intermediate group of individuals whose glucose levels do not reach the criteria for 
diabetes	although	they	are	higher	than	those	considered	normal.	These	people	have	been	defined	
as	having	impaired	fasting	glucose	(IFG)	[fasting	plasma	glucose	(FPG)	levels	between	5.6	mmol/L	
and	6.9	mmol/L,	or	impaired	glucose	tolerance	(IGT)	2-h	values	in	the	oral	glucose	tolerance	test	
(OGTT)	in	the	range	from	7.8	mmol/L	and	11.0	mmol/L.	These	persons	are	referred	to	as	having 
‘pre-diabetes’,	 to	 indicate	 their	 relatively	 high	 risk	 of	 becoming	 diabetics	 in	 the	 future.	 (Expert	
Committee	 on	 the	 Diagnosis	 and	 Classification	 of	 Diabetes	 Mellitus	 2003;	 Genuth	 et	 al	 2003).
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Summary of the current biochemical criteria for diagnosis of Diabetes and abnormal 
blood glucose states according to WHO, 2006:
                 
The diagnostic experience in the former Transkei:
“Comparison of the 1985 WHO and 1997 ADA criteria for the diagnosis of diabetes mellitus 
in black South Africans.  Blanco-Blanco EV, Erasmus RT, AB Okesina, Gqweta Z, Matsha T, Mesa J. 2000. 
JEMDSA, 5(1):54.
In 1997,  the American Diabetes Association (ADA) reviewed the biochemical diagnostic criteria 
for DM discontinuing the use of the OGTT. In 1999, the World Health Organization (WHO) also 
introduced the diagnostic fasting plasma glucose at  >7.7 mmol/L but the diagnostic use of the OGTT 
remained unchanged.  The latest diagnostic cutoff levels for DM would have an impact on the DM 
prevalence figures reported with the old criteria (Levitt & Bradshaw 2006). The earlier prevalence 
needed to be adjusted for the new criteria and new estimates for current and projected burden of 
DM would follow (Shaw et al 1999). Research from different countries had reported lower diagnostic 
sensitivity associated with the single use of the Fasting Plasma Glucose for diagnosis of DM as 
recommended by the ADA. (European Diabetes Epidemiology Group 1999, Ko et al 1998, Gomez-
Perez et al 1998).However, this pattern also needed to be validated in the South African settings.
In 2000, the team of researchers from UNITRA (Blanco et al 2000) re-analysed, using the new 
criteria, the database previously obtained from the OGTT study in factory workers in the former 
Transkei to compare the diagnostic implications of the changes introduced by both international 
diabetes organizations. The prevalences for both DM and IGT and for each set of criteria were:
ADA CRITERIA WHO CRITERIA
DIABETES MELLITUS
2.1%
DIABETES MELLITUS
2.4%
IMPAIRED FASTING GLUCOSE
1.9%
IMPAIRED GLUCOSE TOLERANCE
2.7%
NORMAL FASTING GLUCOSE
96.0%
NORMAL GLUCOSE TOLERANCE
94.9%
 
Implications & Recommendations from the study:
The results suggested that the 1997 ADA criteria were less sensitive for diagnosis in black South 
African diabetics than the OGTT-based WHO criteria as some patients were only identified as 
diabetics by the OGTT criteria. In addition, the intermediate categories of abnormal glycaemia differed 
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substantially with poor agreement for the IGT category resulting from ADA and WHO new criteria. 
However, due to the beneficial implications, our findings supported the lowering of the new criteria 
for Fasting Plasma Glucose. The study also supported the WHO recommendation to continue using 
the OGTT for the diagnosis of DM in the Xhosa population to avoid misleading estimates of DM 
burden, and  also, more importantly, to prevent the further deterioration of patient as a consequence 
of a misdiagnosis. 
The Risk Factors’ experience in the former Transkei:
Importance of family history in type 2 black South African diabetic patients. Erasmus RT, 
Blanco-Blanco E, Okesina AB et al ( 2001 b) Postgrad Med J.; 77:323-325.
The family history of diabetes mellitus has been largely discussed in the medical literature as a 
non-modifiable risk factor for diabetes (Turner, Hattersley & Cook 1992; Simpson 1968). In support 
of the genetic influence attributed the family history for type 2 diabetes some reports had described 
concordance rates as high as 60% to 90% for identical twins which is much higher than the one for 
type 1 diabetes (Newman et al 1987; Barnet et al 1981; Klein et al 1996). In addition, some studies 
had shown increased frequency of type 2 diabetes in first-degree relatives of diabetic patients 
(Permut 1990; Hitman & McCarthy 1991). However, little was known of the phenotypic expression 
and influence of the family history in black African diabetics and therefore the reason for this research. 
Two groups were created. The patient group made up by type 2 patients attending the diabetic clinic 
at Umtata General Hospital between 1996 and 1998, and the control group which included healthy 
subjects recruited from the Umtata district. All participants from both groups were African adults 
of Xhosa ethnic origin. Demographic and health data were collected. The occurrences of positive 
family history between the groups were compared. The results suggested that type 2 diabetes has 
a strong genetic component in black South African diabetics with a predominant tendency to the 
maternal aggregation. Diabetics with positive family history were found to have an earlier age of 
onset of diabetes than the rest.
Implications of the study:
The strong genetic component for diabetes type 2 in black South Africans provides evidence of the 
risk associated with family history. It could be, at least theoretically possible, that the risk of diabetes 
could be lowered by adopting healthier behaviours early in life by the individuals with family history 
of diabetes type 2. These results provide the platform for potential genotypic studies on the offspring 
of diabetic patients.
COMPLICATIONS OF DIABETES MELLITUS
Persistent hyperglycaemia in diabetics is unchaining a series of metabolic abnormalities that 
commonly lead to acute and dangerous complications that constitute medical emergencies. 
A study from Tanzania showed that the prognosis for diabetic patients in tropical Africa, even where 
facilities	for	care	exist,	was	worse	than	for	patients	in	developed	countries	(McLarty	et	al,	1990).	In	
addition, some reports had stressed the higher morbidity and mortality from diabetes among blacks 
from	Africa	as	well	as	from	America	(Castle	&	Wicks	1980).		These	higher	rates	of	complications	
in blacks are related to disparities in diabetes quality of care, disproportionately poor control of 
diabetes as well as associated cardiovascular risk factors such as blood pressure and cholesterol 
(Peek,	Cargill	&	Huang	2007).
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ACUTE COMPLICATIONS
They include the hyperglycaemic crisis, which often require admission of patients to high-care units 
and are associated with high mortality rate. Two principal types are recognized, the ketoacidotic and 
the	hyperosmolar	(Van	Zyl	Smit,	Burch	&	Wilcox	2007;	Nyenwe	et	al	2007;	Ko	et	al	2007).	
They can present as ketoacidosis with or without hyperosmolarity and hyperosmolar non-ketotic 
states	(Ekpebegh	et	al	2010;	Okoro	et	al	2007).	Combinations	of	the	major	types,	are	also	recognized	
and	further	classified	according	to	the	dominant	component	into	“ketoacidosis	with	hyperosmolality”	
and	 “hyperosmolar	 state	with	 ketoacidosis”	 (Levetan,	 Levitt	 &	 Bonnici	 1997).	 The	management	
and	outcome	of	the	hyperglycaemic	crisis	is	usually	different	for	these	two	types	(Small,	Alzard	&	
Maccuish	1988;	Kitabchi	et	al	2001).
The	non-ketotic	hyperosmolar	state,	which	is	common	in	type	2	diabetes,	is	associated	with		higher	
morbidity and mortality than the diabetic ketoacidosis which is attributed mainly to high osmolality 
and	older	age	(MacIsaac	et	al	2002;	Wachtel	et	al	1991).
A	fairly	recent	review	on	diabetes	classified	patients	with	DKA	as	the	initial	manifestation	of	DM	into	
four	categories	resulting	from	the	possible	combinations	(Balasubramanyam	et	al	2008)	which	have	
been	used	 to	separate	atypical	 subtypes	of	diabetes.	 	Combinations	of	 these	classifications	also	
identify	other	variants	or	subtypes	(Katahira	2009).
CHRONIC COMPLICATIONS
The most common body system suffering from the metabolic complications following chronic 
hyperglycaemia is the vascular system. In general, two main groups of complications are distinguished 
according to the location of the damage, which are microvascular and macrovascular.
Microvascular complications:
In terms of long-term complications of diabetes, the mechanism responsible for complications is the 
microvascular damage associated with chronic hyperglycaemia leading to progressive dysfunction and 
failure	of	different	organs,	specially	the	eyes	(diabetic	retinopathy),	kidneys	(diabetic	nephropathy)	
and	the	nerves	(diabetic	neuropathy).	Thus,	blindness,	chronic	renal	failure	and	polyneuropathy	are	
common	chronic	complications	of	diabetes.	(Levitt	et	al	1997;	Motala	et	al	2001)
Regarding diabetic complications in the South African context, a 10-year follow up study in black 
type 1 diabetics in Soweto by Gill, Hiddle & Rolfe in 1995, reported development of retinopathy in 
52%,	peripheral	neuropathy	in	42%,	autonomic	neuropathy	in	47%	and	nephropathy	in	28%.
Mbanya	and	Sobngwi	(2003),	in	a	review	of	diabetic	complications	in	the	African	continent,	described	
prevalences ranging from 15% to 55% for retinopathy. They also reported the presence of retinopathy 
in	around	a	quarter	of	all	newly	diagnosed	type	2	patients.	The	same	study	also	described	diabetes	
as a risk factor for cataracts and retinopathy in relation to the earlier age of onset of diabetes.
Macrovascular complications:
This group results from accelerated atherosclerosis, which is a consequence of the abnormal lipid 
metabolism and specially the increase in LDL-cholesterol and affects important arteries in the body. 
It	includes	mainly:		coronary	heart	disease,	cerebrovascular	disease	(stroke)	and	peripheral	vascular	
disease	(Alberts	et	al	2005;	Kengne,	Amoah	&	Mbanya	2005).	
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The development of combined microvascular and macrovascular disease as in the case of peripheral 
neuropathy and peripheral vascular disease also contribute to the development of diabetic foot 
resulting	in	amputations	and	locomotion	disabilities	(Boulton	et	al	2005;	Mbanya	&	Sobngwi	2003).	
A review of prevalences of diabetic foot in Africa, reported an 8% for South Africa, being the lowest 
among	 the	African	 countries	where	figures	 as	high	as	57%	were	 reported	 in	Nigerian	diabetics	
(Abbas	&	Archibald	(2007).
Another common complication of diabetes is the development of infection. Both, acute and chronic 
infections	are	often	associated	and	superimposed	on	other	complications	in	diabetics	(Joshi	et	al	
1999;	Shah	&	Hux	2003).
PREVENTION OF THE DIABETIC COMPLICATIONS:
The presence of diabetic complications increases not only the suffering of the patients, the 
development of physical disabilities and the mortality rate but also involve increased health costs 
because they require additional health services and the provision of more specialized level of care. 
Since the long-term high blood glucose is the starting point for systemic injury that affects most 
organs in the body, the chronic diabetic complications are preventable, and appropriate glycaemic 
control	is	the	key	to	avoid	them	(Levetan,	Levitt	&	Bonnici	1997;	Motala	et	al	2001).		
Taking	into	consideration	all	the	strategies	with	evident	benefit	on	the	control	of	the	disease	and	
the detection of complications at the earliest phases, when the changes may still be reversible, 
the international diabetes organizations recommend a set of guidelines to optimize the diabetic 
care. This set of recommendations is known as “the standards of medical care in diabetes” 
(American Diabetes Association 2011). 
The components of these comprehensive diabetes evaluation guidelines are:
A-Medical history: Age, characteristics of onset of diabetes, eating patterns, nutritional status, 
physical	 activity,	 weight	 changes,	 diabetes	 education,	 treatment	 history	 (regimens,	 control,	
complications)	and	psychosocial	problems.
B-Physical examination: Height, weight, BMI, blood pressure, fundoscopic examination of eyes, 
comprehensive foot examination and examination of skin and thyroid.
C-Laboratory evaluation:	Glycosylated	Haemoglobin	(HbA1c)	for	the	past	3	months	or	at	least	
within	one	year,	and	the	fasting	lipid	profile	and	liver	function	tests,	test	for	urine	albumin	excretion	
and renal function.
D-Referrals for special care eventually needed: Eye care professional for annual dilated eye 
exam, family planning for women of reproductive age, registered dietician, dentist and mental 
health professional.
Evaluation of attainment of glycaemic control in diabetics:
The	HbA1c	is	a	modification	of	the	normal	haemoglobin	that	occurs	in	proportion	to	the	levels	of	
blood	glucose	during	 the	 life-span	of	 the	 red	blood	cells	 (3	 to	4	months),	 thus,	 	 the	higher	 the	
glucose values during that time the higher the percentage of glycosylation of haemoglobin. This test, 
introduced more than 30 years ago, is still the gold standard for evaluation of long-term glycaemic 
control	of	the	diabetic	patients	(Gonen	et	al	1977).	A	level	of	HbA1c	<	7%		is	the	recommended	
target	for	control	and	prevention	of	chronic	diabetic	complications	(American	Diabetes	Association	
2011).
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The	presence	of	persistent	albuminuria	in	the	range	of	30–299	mg/24	h	(known	as	microalbuminuria)	
is	a	well-established	marker	for	development	of	nephropathy	in	type	2	diabetes	and	for	the	increased	
risk	for	cardiovascular	diseases.	(Garg	&	Barris	2007;	American	Diabetes	Association		2011).	
Commonly suggested strategies in diabetic control such as behavioural changes in lifestyle 
resulting in a healthier diet, regular physical activity and weight control. Increasing diabetes education 
and awareness of complications, early diagnosis of the disease, adherence to treatment, access to 
health	care,	early	detection	of	complications	(clinical	and	biochemical)	are	also	considered	under	
“the standards of medical care in diabetes”. Hence, strict adherence to these international guidelines 
warrants the most complete possible diabetic control.
The former Transkei experience on chronic diabetes complications:
Prevalence of diabetic retinopathy in black South African diabetics attending a tertiary clinic 
in the Eastern Cape. Surka J, Erasmus RT, Blanco-Blanco E, Salazar C, Okesina AB. 2001, 
JEMDSA, 6 (1): 40.
Diabetic Retinopathy (DR) is a common chronic complication of diabetes and is also one of the 
most devastating (Javitt & Aielo 1996). DR had been reported the leading cause of new blindness 
in people aged 25-74 years in developed countries (DCCT 1995). Some well-defined studies had 
documented prevalences of diabetic retinopathy in (DCCT 1995, Rolfe 1988, Erasmus et al 1989a) 
but reports in the black population of South Africa were scarce. The records of diabetic patients 
attending both the Diabetic and Eye Clinic at UGH were analysed to assess glycaemic control, 
duration of diabetes and severity of the retinal damage.
The overall prevalence of diabetic retinopathy was 21.8%. The stratified prevalences were similar 
in newly diagnosed diabetics and those with duration of diabetes <10 years(13%) while in patients 
with diabetes for >10 years it increased significantly (40.7%). The frequency and severity of diabetic 
retinopathy showed negative association with the deterioration of glycaemic control measured by 
Glycosylated Haemoglobin.
Implications of the study: The prevalence of diabetic retinopathy in the studied black South African 
population of the former Transkei was identified and the regular fundoscopic examination was 
introduced for all diabetic patients receiving care at UGH.
The high prevalence of retinopathy in newly diagnosed diabetics suggested the possibility of high 
prevalence of undiagnosed diabetes mellitus in the studied population which could explain the 
presence of chronic complications identified at the time diagnosis was made. 
Implications: 
The confirmation of the prevalence of undiagnosed diabetics requires further community-based 
studies. 
Hypertension, proteinuria and renal insufficiency in black South Africans with non-insulin 
dependent diabetes.  Erasmus RT, Blanco-Blanco E, Okesina AB.  1999(b), Diabetes International. 
9(3): 66-69. 
This study was motivated by the evidence of the increasing burden of diabetes in South Africa 
specifically in the urban black African population (Levitt et al 1993 urban African). There was also 
evidence of frequent association of diabetes with hypertension reported by the National Health and 
Nutrition Survey (1976-1980) from USA for black Americans (Current Population Survey 1989), and 
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also a similar trend reported in urban and rural black-South Africans (Mollentze et al 1995). Renal 
insufficiency was a relatively common complication of hypertension in black populations (Mhando 
et al 1980; Nelson et al 1988)
Data was gathered and analysed for blood pressure, presence of microalbuminuria and/or renal 
insufficiency as well as obesity in black South Africans attending the diabetic clinic at UGH. 
The overall prevalence of hypertension in diabetics was 53%. This pattern was similar to other 
studies reported from black African populations. No significant differences for age, gender, duration 
of diabetes, obesity and type of treatment were found. Both proteinuria and azotaemia were 
independently associated with the development of hypertension. 
Implications:
There is need to establish early interventions to predict the development of hypertension and renal 
failure in diabetic patients as the presence of these complications implies an increase in the economic 
burden of diabetes due to higher morbidity.
The experience on acute metabolic diabetic complications in the former Transkei: 
Hyperglycaemic crisis in the Eastern Cape province of South Africa: high mortality and 
association of hyperosmolar ketoacidosis with a new diagnosis of diabetes. (Ekpebegh CO, 
Longo-Mbenza B, Akinrinmade A, Blanco-Blanco E, Badri M,  Levitt NS  2010, SAMJ, 100 (12): 
822-826) 
Literature on the clinical, laboratory findings and outcome of the combined presentation as 
“hyperosmolar diabetic ketoacidosis” from different populations is scarce (Zouvanis et al 1997). The 
frequency and outcome of these metabolic complications of diabetes, in the population served by 
the Nelson Mandela Academic Hospital in Umtata, was unknown. This research intended to cover 
such description by describing the findings of the hyperglycaemic complications in a period of two 
years. Hyperglycaemic crisis accounted for 43.5% of all diabetic admissions in the period studied. 
They comprised, in order of frequency, hyperglycaemia (HG) with 44.2%, non-hyperosmolar diabetic 
ketoacidosis with 36.1%, hyperosmolar hyperglycaemic state (HHS) with 10.8% and hyperosmolar 
diabetic ketoacidosis (HDKA) with 8.9%. 
The study allowed the identification of the Hyperosmolar Diabetic Ketoacidosis (HDKA) as the most 
common hyperglycaemic presentation associated with the newly diagnosed type-2 diabetes, which 
was also frequently associated with altered level of consciousness and an alarmingly high mortality 
rate of 37.5%; in fact, the highest mortality among all diabetic hyperglycaemic crises. This mortality 
rate was about twice the one reported in other South African study in 1997 (Zouvanis et al).
Implications: 
The high association of ketoacidosis in addition to the hyperosmolarity reported in this study for 
type 2 diabetics implies that newly diagnosed type diabetics, at least in this population, are often 
presenting with a much more complex metabolic model, which requires a somewhat different 
therapeutic approach. 
Early identification of the HDKA and awareness of its frequency in the population are the first steps 
to improve the outcome of these patients.  
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Recommendations: 
The diabetes subtype regarding insulin reserve and immunity status of these patients needs to be 
investigated.
The former Transkei experience of acute metabolic complications of diabetes:
Islet immunity and beta cell reserve of indigenous black South Africans with ketoacidosis at 
initial diagnosis of diabetes. Ekpebegh C; Longo-Mbenza B; Blanco-Blanco E.  2013, Ethn Dis.; 
23[2]:196-201
A previous research had shown high prevalence of ketoacidosis combined with hyperosmolality 
(HDKA) in newly diagnosed black South African patients associated with the highest mortality rate 
of all hyperglycaemic crises (Ekpebegh et al 2010). Although this pattern had been described before 
there was little information on the specific phenotype of the patients in this specific population.  A 
recent review classified patients with DKA as the initial manifestation of DM based on islet cell 
immunity (anti-Glutamic acid decarboxylase antibody) and beta cell reserve into four categories 
resulting from these combinations (Balasubramanyam et al 2008).  Indigenous Xhosa black South 
Africans with ketoacidosis as the initial manifestation of diabetes were tested for Islet immunity using 
serum anti-glutamic acid decarboxylase 65 (GAD) antibody beta cell reserve using serum C-peptide 
after 1 mg of intravenous glucagon.
Results:
       (A+ b-) antibody positive and beta cell reserve deplete:  22.5% 
 (A+ b+) antibody positive and beta cell reserve replete:  4.2% 
 (A+b-) antibody negative and beta cell reserve deplete: 26.8% 
 (A+b+) antibody negative and beta cell reserve replete: 46.5% 
The most prevalent pattern was A-b+ suggesting that these patients with ketoacidosis as the initial 
manifestation of diabetes had islet immunity, beta cell reserve status and clinical profiles of type 2 
diabetes. 
Implications: 
The study contributed to establish the subtype of diabetes of those patients presenting with atypical 
acute metabolic complications (hospital-based). It brings to the attention of doctors the likely risks, 
complications and specific therapies required for newly diagnosed patients from this population.  
Recommendations: 
The prevalence of these phenotypes in the rest of the diabetic population, specifically for this 
community, necessitates further studies.  
The former Transkei experience on the control and prevention of diabetes complications:
Assessment of glycaemic control in stable type 2 black South African diabetics attending a 
peri-urban clinic.  Erasmus RT, Blanco-Blanco EV, Okesina AB et al. 1999(a). Postgrad Med J, 
75(888):603-606.
There was growing evidence suggesting that the prevalence of diabetes mellitus in black South 
Africans had been steadily rising over the last two decades (Levitt et al 1993). Some studies had 
described complications observed in diabetics admitted to hospital wards and even post-mortem 
findings in diabetics with acute metabolic complications but little was known about the glycaemic 
control of stable black African diabetics attending the out-patient clinics (Bhook 1976; US Department 
of Health and Human Services 1990). 
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This study was based at Umtata General Hospital;  a major referral centre for the former homeland 
of Transkei. The biochemical determination of glycosylated haemoglobin  (HbA1c) was used to 
assess the long-term glycaemic control. HbA1c values <7% were considered as ‘attaining the target 
for control’, between 7.1% and 8.9% it was considered “acceptable”  whilst >8.9% was ‘poor’.  
The results showed poor  glycaemic control in the majority of diabetics irrespective of gender, duration 
of diabetes, adiposity (obesity), educational status, having or not received dietary counselling and, 
type of pharmacological treatment. Only 20% reached the target for glycaemic control. Possible 
explanations were related to lack of adherence to advised management and the insufficient dietary 
counselling probably conditioned by shortage of clinic staff. 
Implications:
Obesity was present in almost 80% of patients but it did not show any dependence with the glycaemic 
control. The need for behavioural changes through health educational programmes for both patient 
and healthcare staff was identified. Intervention strategies were implemented with the collaborative 
engagement of the departments of Dietetics, Nursing, Internal Medicine and Chemical Pathology 
based on reported supportive evidence.
Recommendations:
The results from this community enquiry completely match our observations from the diabetic patients. 
Thus, the implications of obesity and its determinants in this community merit further investigation. 
The implementation of a continuous auditing is recommended to further evaluate attainment of 
glycaemic control and potential interfering barriers. 
Standards of care of diabetic patients at a peri-urban hospital in the Eastern Cape. 
Erasmus RT & Blanco-Blanco EV.  2000, SA F Pract  ; 22(31)17: -20
Following the confirmation of poor glycaemic control in patients attending the diabetic clinic at UGH 
from a previous research conducted and published (Erasmus et al 2000) the quality of diabetic care 
provided by the clinic was targeted for evaluation. One of the most effective strategies for attaining 
control of diabetes and prevent its acute and chronic complications is the use of appropriate and 
standardized management guidelines in the provision of the continuing medical care (Wayne 1988; 
Levitt et al 1997; Mash & Levitt 1999).
The standards of the diabetic care provided by UGH were assessed using a structured questionnaire 
to evaluate their agreement with recommended international guidelines (Alberti & Gries 1998; 
Santiago 1993). The evaluation referred to two main areas: the processes of care, and, the outcome 
of the care. Regarding the first criteria, it was found that only 48% of the 23 recommended standards 
for the process were fully implemented. The original standards not been met were identified. Most 
of them were related to partial physical examination or laboratory investigations and to deficient 
patients’ record keeping.  
Implications:
The identification of the suboptimal standards of medical care for diabetic patients served to 
understand the problems faced by the clinic and to propose a specific strategy for improvement. 
This research provided the feedback required for the improvement of the quality of the healthcare 
provided to the population. The aspects related to the process of care were optimized and a series 
of diabetes education workshops were organized for both patients and health personnel, specific 
clinic guidelines were developed and the record keeping was improved. 
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These results were published in the Postgraduate Medical Journal to share the experience and 
awareness with the medical practitioners in the primary health care (Erasmus et al 2000). 
The dietary pattern of black African diabetic patients attending a tertiary care clinic in the 
Eastern Cape.    Mdubeki N, Blanco-Blanco E, Erasmus RT (2001) JEMDSA (6):1, 44.
Recent reports had suggested that a considerable proportion of black diabetics attending the diabetic 
clinic at UGH were having poor glycaemic control (Erasmus et al, 1999a). Among the factors that 
contribute to poor control, the patient education with regard to diet and physical exercise plays an 
important role (Rubin, Peyrot & Saudek, 1989, 1991). Previous studies also reported the effect 
of urbanisation on the diet of the population. Such changes were suspected to be happening as 
Umtata is mostly a semi-urban area facing expansion in different directions.  The study aimed to 
investigate the variety of foods regularly eaten by the diabetic patients (food frequency questionnaire) 
in an attempt to identify potential sources of inappropriate glycaemic control and association with 
increased adiposity and glycaemic control (Storlien et al 1996). 
Randomly selected participants, 62% living in rural areas and 38% from inside the perimeter of the 
township, were interviewed for food frequency patterns whilst 77% of the total acknowledged having 
received dietary advice.
The results showed that the food types most regularly consumed (>90%) were starchy foods. Foods 
eaten in moderate quantities (40-70%) were isigwampa, umbona, umqa and amagwinya. Foods 
that were not eaten frequently (<30%) were oats, legumes, cereals and pasta. Consumption of 
vegetables was variable. The most popular meat eaten was chicken, followed by beef. Fish was 
seldom eaten. About half of the patients were using animal fat for cooking. 
Results suggested that the poor diet control, due to high frequency of starchy foods and animal 
fats, could be at least to certain extent contributing to the overall poor glycaemic control reported on 
those patients.
There were no differences in the pattern reported between patients who had and who had not 
received dietary advice. 
Implications:
Training workshops were organized for clinic staff and patients. 
The dietetic advice given at the clinic addressed the proper proportions of foods and some 
recommendations to reduce the intake of animal fats. 
Recommendations:
Further investigation of the nutritional analysis and food portions in conjunction with the pattern of 
physical activity was recommended. The effect of dietary advice on diabetics’ behaviour and its 
relationship with educational background also recalls for further research. Dietary advices must be 
revised to be in agreement with the local cultural food pattern.
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Summary of the sequence of events initiated with the suspicion of DM: 
The evaluation of glycaemic control and evaluation for chronic complications becomes then a cycle 
that allow the individual management interventions according to the evolution of the diabetes. 
Until this point, I have discussed the implications of diabetes mellitus for the individual 
patient and the diabetic population. However, I also want to call the attention on the 
prevalence of diabetes (frequency of the disease out of the total population), the burden 
of diabetes in terms of total number of people living with the disease as well as the 
implications of those figures at international, regional and national scale.
THE GLOBAL PREVALENCE & GLOBAL BURDEN OF DIABETES 
Diabetes mellitus was considered a disease of minor importance to the world health for long time. 
However, the past three decades have seen a worldwide explosion in the number of people diagnosed 
with	type	2	diabetes	(King	&	Rewers	1991).	This	 increase	has	been	related	to	global	changes	in	
the human environment, behaviour and the lifestyle associated with increasing rates of obesity. In 
addition, worldwide achievements in public health with the elimination of many of the communicable 
diseases	during	the	20th century resulted in longer life expectancy and higher prevalence of diabetes 
associated with the ageing population. The current global diabetes epidemic has become one of the 
main	health	challenges	for	the	21st	century	(Zimmet,	Alberti,	Shaw	2001;	Shaw,	Sicree	&	Zimmet	
2010).
In	1993,	 the	WHO	Ad	Hoc	Diabetes	Reporting	Group	 (King	&	Rewers	1993)	published	a	 report	
with standardized global estimates for the prevalence of diabetes mellitus based on data from 75 
communities	and	32	countries.	It	is	important	to	note	that	some	epidemiological	publications	from	
the	early	1990’s	did	not	report	separately	type	1	from	type	2	diabetes,	but	taking	into	account	that	
that	type	1	is	just	a	fraction	of	the	global	figures,	the	use	of	data	that	included	both	types	was	not	
expected to have a major effect on the estimates. 
Different countries had already been reporting relatively high prevalence of diabetes mellitus and 
this study called the attention to the worldwide dimension of the problem not only for diabetes 
mellitus	but	also	for	the	pre-diabetic	state	of	Impaired	Glucose	Tolerance	(IGT).	The	global	estimate	
of	people	with	diabetes	from	this	report	for	the	year	2000	was	154	million.	The	data	used	in	this	
study	was	 insufficient	 to	 estimate	 the	 prevalence	 for	 individual	 countries	 and	 to	make	 accurate	
predictions. However, the impact of this article has led to some global recommendations and target 
settings as well as to awareness of the need for more community-based data from the different 
countries.  
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In 1998, King, Aubert & Herman carried out a further version in which they analysed the global 
database	 collected	 by	 WHO	 taking	 into	 consideration	 some	 additional	 parameters	 such	 as	 sex	
ratio, urban-rural ratio and age structure of the population. This information was combined with 
demographic estimates and projections provided by the United Nations to create a new global estimate 
of prevalence for diabetes mellitus as well as the estimated prevalence for each of the countries 
of	the	world	and	their	predicted	values	for	three	points	 in	time:	1995,	2000	and	2025.	The	new	
estimate	for	the	year	2000	increased	by	11%,		which	means	171	million	as	compared	to	the	previous	
1990 burden number of 154 million. The study resulted in improved estimates for the prevalence 
of diabetes mellitus in the adult population. However, in addition to the global vision, it introduced 
estimates of diabetes prevalence for each country in the world in details that included urban-rural 
ratio, sex ratio, age-structure of population. The latest, more accurate, estimates also included three 
points in time. Such improved sets of estimates allowed the comparison of the prevalence of diabetes 
from the different countries across the world and across the major world regions approved by the 
IDF	(Wild	et	al	2004).	The	study	predicted	for	the	period	from	1995	to	2025	a	worldwide	growth	
of adult population by 64% with increase in prevalence of diabetes mellitus by 35%, which would 
result	in	an	increase	by	122%	in	the	number	of	people	with	diabetes.	These	impacting	figures	of	the	
burden	of	1990	supported	previous	forecasts	of	the	global	epidemic	growth	of	diabetes	for	the	21st
century.  In this report, the extrapolation of available suitable data was used to 
determine the estimates whenever  actual survey data was lacking, for example, all Sub-
Saharan	 Africa	 was	 estimated	 using	 data	 from	 Tanzania.	 	 (King,	 Aubert	 &	 Herman	 1998).
These studies emphasized the need for survey studies from the different communities and countries 
in order to obtain accurate data for the current and future prevalences of diabetes. The estimates 
were set as essential tools to guide the healthcare strategy to manage the burden of diabetes and 
to	identify	specific	measures	expected	to	neutralize	the	growing	prevalence	of	diabetes	at	all	levels	
(Amos,	McCarty	&	Zimmet	1997).	
With	the	subsequent	rise	of	international	awareness,	some	national	diabetes	surveillance	programs	
developed, providing additional information about diabetes associated disorders and complications 
and,	the	World	Health	Organization	recommended	the	use	of	the	prevalence	of	diabetes	as	a	basic	
health	indicator	(World	Health	Organization	1997).	
Summary of global statistics for diabetes in 2012 
More than 371 million people have diabetes •	
The number of people with diabetes is increasing in every country•	
80% of people with diabetes live in low- and middle-income countries•	
The greatest number of people with diabetes are between 40 to 59 years of age•	
Half of people with diabetes are undiagnosed•	
4.8 million people died due to diabetes•	
More than 471 billion USD was spent on healthcare for diabetes.•	
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Figure 1. Prevalence of diabetes (%) for world adult population (20-79 years), 2011
     
Source: IDF Diabetes Atlas, 2011    http://www.idf.org/diabetesatlas
Estimated increase in prevalence for 2030 based on the 2011 estimates (20-79 years)
Source: IDF Diabetes Atlas, 2011    http://www.idf.org/diabetesatlas
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Figure 2. Percentage of total cases of diabetes (20-79 years) by IDF region, 2011 & 
2030:                 
AFR: Africa    EUR: Europe       WP: Western Pacific 
MENA: Middle East and North Africa SEA: South-East Asia 
NAC: North America and Caribbean SACA: South and Central America      
 
Source: IDF Diabetes Atlas, 2011    http://www.idf.org/diabetesatlas
According to the predictions based on estimates and population growth, the increase in the burden 
of	diabetes	by	2030	is	expected	to	have	a	specific	regional	pattern	as	shown	in	the	above	graph	
(Shaw,	Sicree	&	Zimmet	2010;	International	Diabetes	Federation	2011).	As	shown	 in	 the	graph,	
the	 diabetes	 prevalence	 estimates	 for	 2011	 and	 2030	will	 not	 change	much	within	 each	major	
world region. However, in terms of the total number of people living with diabetes, most of the 
increase	will	 emerge	 from	 specific	 areas	 such	 as	 South-East	 Asia	 and	 	 Africa,	 because	 of	 their	
higher expected population growth rates. The same pattern applies when comparing the prospected 
diabetes	prevalence	figures	of	developed	versus	developing	countries.	The	individual	prevalences	
translate	into	burden	of	diabetes	(total	number	of	people	living	with	diabetes)	as	a	function	of	the	
population	growth	(Shaw,	Sicree	&	Zimmet	2010;	King,	Aubert	&	Herman	1998;	Levitt	&	Bradshaw	
2006).	
According	to	the	WHO	projections,	diabetes	will	be	the	seventh	leading	cause	of	death	by	2030.	
Healthy diet, regular physical activity, maintaining a normal body weight and avoiding tobacco use 
can	prevent	or	delay	the	onset	of	type	2	diabetes	(International	Diabetes	Federation	2011).
In	2004,	Wild	et	al	reported	new	estimates	for	the	prevalence	of	diabetes	for	the	year	2000	and	their	
projections	for	2030	published	a	follow	up	investigation	on	the	world	and	country-based	estimates	
of	1990.	The	resulting	new	estimate	for	South	Africa	in	the	year	2000	for	prevalence	of	diabetes	
was based on the data published by Levitt et all in 1993 from urban Africans in Cape Town. The 
updated	estimate	published	in	2010	by	Shaw,	Sicree	&	Zimmet	expanded	the	data	which	included	
three	additional	studies	from	South	Africa	published	by	Omar	et	al	(1993),	Erasmus	et	al	(2001a)	
and	Motala	et	al	(2008).
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THE AFRICAN BURDEN OF DIABETES MELLITUS
The	estimated	global	total	of	persons	living	with	diabetes	mellitus	in	2007	was	124	million	whilst	for	
2010	it	was	221	million.	In	Africa	the	total	estimated	was	7.8	million	with		4.5		million	in	North	Africa,	
1.08	million	in	Western	Africa,	1.05	million	in	Eastern	Africa,	0.26	million	in	Central	Africa	and	0.82	
million	in	Southern	Africa	(International	Diabetes	Federation	2011).	
The main features of the burden of diabetes as estimated for 2011 and 2030 in AFRICA 
are summarized as follows: 
                 
Source: IDF Diabetes Atlas, 2011    http://www.idf.org/diabetesatlas
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The variation in the estimates for diabetes mellitus prevalence in Africa shows some geographic 
concentration	in	specific	areas	where	Southern	Africa	exhibits	the	highest	prevalence.	
 Figure 3. Prevalence (%) estimates of diabetes (20-79 years), 2011, Africa Region:
   
Source: IDF Diabetes Atlas, 2011    http://www.idf.org/diabetesatlas
The prevalences of diabetes for Sub-Saharan Africa also show extensive regional variations which 
are	independent	of	the	diagnostic	criteria	used	for	diabetes	(Mbanya	et	al	2010).	
Another	report	by	Levitt	in	2000	using	standardised	diagnostic	reported	age-standardized	prevalences	
of	diabetes	lower	than	2%	from	two	communities	in	Cameroon	and	four	communities	in	Tanzania	
whilst	in	five	investigated	communities	in	South	Africa	the	prevalences	ranged	from	4%	to	8%.
THE SOUTH AFRICAN BURDEN OF DIABETES MELLITUS
The initial report of the burden of diabetes as published in 1998 by King, Aubert & Herman, faced a 
lack of local statistical research data from South African. Thus, the 1990 estimate for prevalence of 
diabetes in South Africa used an extrapolation of available data from Tanzania reported by McLarty 
et al in 1989. The use of extrapolated data generated diabetes prevalence estimates of 1.4% for 
1995	and	2000	and	1.6%	for	the	year	2025.	
In South Africa, after 1994, the research publications on the epidemiology of diabetes were still 
scarce.	The	first	demographic	report	emerged	from	The	South	African	Demographic	Health	Survey	
(DHS)	conducted	in	1998.	This	survey	resulted	in	a	large	amount	of	internal	data	regarding	health	
issues from more than 13 000 adult male and female participants starting from the age of 15 years. 
The	resulting	prevalences	of	diabetes	by	province	showed	significant	differences	as	compared	to	
previously	published	estimates	as	was	the	case	for	the	prevalences	per	population	group	(Steyn,	
Fourie	&	Temple	2006,	Chapter	10,	p110).	The	DHS	(1998)	was	a	breakthrough	in	terms	of	making	
available information generated within the country; new estimates, which were closer to the South 
African	 reality,	were	calculated	and	even	stratified	per	province,	age	groups,	population	groups,	
28
urban-rural ratio and sex ratio. However, the data still had limitations arising from the self-reported 
nature of the data collected; the report missed the undiagnosed diabetics.
In summary the diabetes prevalence resulting from the DHS 1998 were:
  ALL  URBAN  NON-RURAL
Males			 2.4%			 2.9%	 	 1.7%
Females	 3.7%	 	 4.4%	 	 2.7%
In	2003,	a	second	round	of	the	South	African	DHS	led	to	a	new	report	but	the	self-reported	prevalences	
for	diabetes	did	not	change	significantly	between	them	both	(Levitt	NS.	2008).
Table 2. Example of the original DHS 1998 data report. The specific section referred to 
“chronic disease prevalence among men”. 
Source: Department of Health, 1998. South Africa Demographic and Health Survey, 1998: Full report. Pretoria: South Africa (table 
10.3).
The table shows a portion of the original table 10.3 of the DHS 1998 report, which illustrates 
the considerable degree of details in the information collected and an example of the variations 
of prevalence for diabetes across the provinces. The high statistical variability observed in the 
reported prevalences of diabetes from different geographic areas and socioeconomic settings 
even within the same populations groups supports the notion that each of the various risk 
factors	associated	with	diabetes	do	not	have	the	same	intensity	and	influence	across	the	country.	
It also emphasizes the need for developing community-based research that provides better 
perception	of	 the	complexity	 ruling	 the	different	settings	(Zimmet	1999).	The	evidence	of	 those	
particularities	 supports	 the	 inferred	 principle	 that	 the	 identification	 of	 the	 pattern	 inherent	 to	
each community is the key to identify the relevant strategies to counteract the rampant growth 
of	 diabetes	 (King,	 Aubert	 &	 Herman,	 1998;	 Shaw,	 Sicree	 &	 Zimmet	 2010;	 Hall	 et	 al	 2011).	
BACKGROUND
CHARACTERISTIC
S
HYPER-
TENSION
ISCHAEMIC
HEART
DISEASE
STROKE HYPERLI-
PIDAEMIA
DIABETES EMPHYSEMA
CHRONIC
BRONCHITIS
ASTHMA CANCER NUMBER
AGE
15-24 0.2 0.3 0 0.2 0.1 2.3 2.9 0.0 1.812
25-34 2.7 1.9 0.7 1.2 0.8 2.8 1.9 0.2 1.120
35-44 7.5 2.9 0.5 1.8 2.5 3.0 4.0 0.0 1.003
45-54 18.0 4.6 2.0 4.3 5.4 8.7 7.7 0.6 700
55-64 16.9 6.6 2.0 3.8 7.9 6.7 5.4 0.1 514
65+ 25.0 7.8 2.3 3.7 4.8 8.6 7.3 1.6 502
Residence
URBAN 9.4 3.1 0.7 2.2 2.9 4.9 4.1 0.3 3.569
NON-URBAN 5.5 2.4 1.2 1.2 1.7 3.2 3.2 0.2 2.102
PROVINCE
WESTERN CAPE 9.2 2.8 0.9 1.7 3.2 9.4 4.6 0.4 721
EASTERN CAPE 9.0 3.5 0.9 1.3 2.7 5.2 4.7 0.3 758
NORTHERN CAPE 13.2 4.1 1.3 1.8 2.1 5.6 3.2 0.2 135
FREE STATE 7.2 2.6 0.4 1.4 1.3 0.7 1.3 0.4 444
KWAZULU-NATAL 7.5 3.2 1.6 1.7 3.1 3.4 4.9 0.2 1.064
NORTH WEST 4.8 2.4 0.3 1.1 0.9 1.4 2.4 0.0 551
GAUTENG 10.7 3.1 0.7 4.0 3.3 5.7 4.5 0.5 1.099
MPUMALANGA 4.9 1.8 1.1 0.9 2.0 2.9 2.9 0.2 378
NORTHERN 4.4 2.0 0.5 0.2 0.9 1.1 1.3 0.2 521
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COMMUNITY-BASED STUDIES IN SOUTH AFRICA: 
In	the	late	90’,	some	cross-sectional	prevalence	studies	from	South	Africa	were	published.	The	first	
one	by	Charlton,	Levitt	&	Lombard	(1997)	had	some	limitations,	as	it	was	restricted	to	the	elderly	
sub-population of coloured South Africans. Another one by Levitt et al followed this report in 1999, 
which	reported	an	age-standardised	prevalence	of	10.8%	in	a	coloured	community	of	the	Western	
Cape.	(Steyn,	Fourie	&	Temple	2006,	Chapter	10,	p.111).	
In	2001	a	study	by	Erasmus	et	al	(2001a)	done	in	Black	Africans	in	Umtata	was	published	reporting	
an age-adjusted prevalence of 4.5%. In both studies the age-adjusted prevalences of diabetes were 
found to be higher than the ones previously reported by the DHS for their respective provinces 
and	population	groups.		These	studies	provided	the	first	South	African	reports	of	cross-sectional	
community research data, and the information was used in the following DM burden estimates 
(Shaw,	Sicree	&	Zimmet	2010,	Hall	et	al	2011).	A	few	other	papers	have	been	published	on	other	
population	groups	 in	South	Africa.	In	the	year	2000	there	were	at	 least	6	prevalence	reports	on	
diabetes published from different population groups in South Africa which were used in the following 
works on re-estimates for the world, the IDF regions and the different countries. 
Table 3.  Available research reports on prevalence of diabetes from South Africa by 2000 
as per records of the IDF Diabetes Atlas:
Population Region (number of par-
ticipants)
Preva-
lence 
(%)
Age 
range 
Reference
African Cape	Town,	urban	(729) 8.0 30 + Diabet Care 1993;16:601
African QwaQwa,	rural	(853) 4.8 25	+ S Afr Med J 1995;85:90
Mangaung,	urban	(758) 6.0
African Durban,	urban	(479) 5.3 15 + S Afr Med J 1993;83:641
Mixed Cape	Town,	urban	(200) 28.7 65 + S	Afr	Med	J	1997;87	(suppl	
3):364
Mixed Cape	Town,	peri-urban	(974) 10.8 15 - 86 Diabet Med 1999;16:946
European Durban,	urban	(396) 3.0 15 - 69 S	Afr	Med	J	1994;84:257
Indian Durban,	urban	(2479) 13.0 15 + Diabet Care 1994;17:70
 
Source: IDF Diabetes Atlas, 2011    http://www.idf.org/diabetesatlas
The experience in the former Transkei:
Prevalence of diabetes mellitus and impaired glucose tolerance in factory workers from 
Transkei, South Africa.  Erasmus RT; Blanco EB; Okesina AB et al  2001(a). SAMJ, 91(2 I):157-
160.
The 1990 and 1995 reports on the global burden of DM and its projected increase with epidemic 
dimension had been reported (King & Rewers 1991, 1993). The published figures put in evidence 
the high variability of the prevalence of type 2 diabetes mellitus for the different communities and 
population groups even in the same geographic areas Ahren & Corrigan 1984, McLarty et al 1989, 
Erasmus et al 1989b).
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Other reports had demonstrated that the increase in prevalence of diabetes in developing countries, 
which in some instances exceeded that of the developed ones. Data regarding the prevalence 
of diabetes for the South African population was lacking. The South African Demographic Health 
Survey of 1998 (DHS report 1998) provided extensive information from all geographic latitudes, 
population groups and ages but the data had the limitations inherent to a self-reported process, 
and, in addition, previous studies had reported a relatively high number of undiagnosed diabetics 
in the African region. Some community-based research reports were emerging with information 
from specific South African populations, (Levitt et al 1993; Omar et al, 1993) but very scarce 
community-explored data was available on the prevalence of DM in the Xhosa population of the 
former Transkei where the University of Transkei is located. There was a need for a response from 
the local community to investigate the issue and to contribute to the identification of a more realistic 
estimate of the prevalence of DM in the country, the provinces and their individual communities and 
population groups. 
The strategy followed was the recruitment of workers from two of the largest factories in Umtata. 
An oral glucose tolerance test (OGTT) was performed on each of the 374 black African Xhosa 
respondents with ages ranging from 20 to 69 years. Basic personal demographic and anthropometric 
data was also collected. Statistical transformation of frequencies to the standard world population 
was used to obtain age-adjusted prevalences. 
The critical values obtained were:
Diabetes mellitus:  Crude prevalence: 2.5%   Age-standardized:  4.5 % (CI 1.54; 7.42)
Impaired Glucose Tolerance: Crude prevalence: 2.7%   Age-standardized: 5.1 % (CI 2.45; 
5.51)
A remarkable finding of this research was that 89% of the workers found to be diabetics had not 
been diagnosed before which suggests that the prevalence of undiagnosed diabetes in the Xhosa 
community around Umtata could be considerably high. However, the confirmation of these figures 
merits further exploration.  In contrast with most reports from similar populations, obesity was only 
present in 22% of workers with no gender differences. It was also a contrasting finding the lack of 
association between obesity and diabetes mellitus although there was some relationship between 
the IGT and the presence of overweight. Some association was expected,  taking into consideration 
that, the frequency of obesity, reported for stable patients attending the diabetic clinic at Umtata 
General Hospital, was 79.4%. Further epidemiological studies on randomized larger samples were 
recommended to explore the prevalence of type 1 DM and the impact of obesity on the prevalence 
of DM in the community studied.
Implications: 
The most relevant outcome was the establishment, for the first time, of the crude and the age-
adjusted prevalences of DM and IGT for the Xhosa population of Umtata obtained by direct diagnostic 
testing of a sample from the community. The results were published and shared, nationally and 
internationally. These figures have served as reference by other researchers to compare to the 
other South African communities. They have also been included in the data used to generate new 
estimates of the burden of DM in South Africa and in closely related countries where this kind of 
information has not been available (Shaw, Sicree & Zimmet 2010, Hall et al 2011).
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DIABETES AND THE BURDEN OF COMMUNICABLE DISEASES IN AFRICA
One	overriding	influence	to	consider	when	estimating	the	prevalence	of	non-communicable	diseases	
in the African region is the potential opposing effect exerted by co-existing epidemics of communicable 
diseases	such	as	HIV/AIDS	and	tuberculosis.	Changes	in	the	population	structure	and	the	population	
growth rate could prevent the doubling effect expected in future estimates of prevalence for diabetes 
(Levitt	&	Bradshaw	2006).	Hence,	we	must	consider	the	potential	impact	of	the	HIV/AIDS	epidemic	
on the population growth when estimating the prevalence of diabetes. 
The HIV burden and its effects on the estimates for prevalence of diabetes in South 
Africa:
In 1999, Panz and Joffe reported an estimated increase in the burden of diabetes in South Africa from 
1.6	million	in	1995	to	3.5	million	in	2010.	The	2010	predicted	prevalence	of	diabetes,	recalculated	in	
view	of	the	effect	of	HIV/AIDS	was	only	100	000	cases	less.	In	2005,	a	study	by	Levitt	&	Bradshaw	
using	the	2001	census	data	published	improved	estimates	of	the	burden	of	HIV/AIDS	and	prevalence	
of diabetes. The result was an estimated reduction of the population growth from 1.8% per annum 
in	the	absence	of	HIV/AIDS	to	1.1%	per	annum	because	of	the	HIV/AIDS	epidemic.	
Levitt also revised the estimates in 2008 with new data reported and using more 
complex prediction models, which still supported the South African population growth 
rate to increase at 1.5%. Thus, the prevalence of diabetes would also increase, resulting 
only in little change compared to the previous estimates for the burden of diabetes. 
Similar extrapolations support the projected estimates for the rest of Africa. We must 
also consider that the expansion of the ARV program is lowering the impact of the HIV/
AIDS epidemic on the population growth and, in addition, a growing number of studies 
are reporting increased association of diabetes/metabolic syndrome with the use of 
ARV therapy. 
Tuberculosis and the prevalence of diabetes in South Africa:
The increased susceptibility to infections secondary to the metabolic effects of diabetes mellitus is a 
well-documented fact supported by the high incidence of sepsis as acute complications in diabetic 
patients	(Joshi	et	al	1999,	Shah	&	Hux	2003).	
Recent	studies	demonstrated	increased	chance	of	developing	tuberculosis	by	at	least	2.5	times	in	the	
presence	of	diabetes	(Ottmani	et	al	in	2010).	In	addition,	a	person	with	diabetes	and	tuberculosis	
is more likely to fail tuberculosis treatment and more likely to die from tuberculosis than a person 
without	diabetes	(Goldhaber-Fiebert	et	al		2011,	Baker	et	al	2011).		
Diabetic	control	is	beneficial	in	reducing	the	risks	of	tuberculosis	although	the	association	of	these	
diseases	also	depends	on	other	social	determinants	(Leung	et	al	2008).	The	increasing	burden	of	
diabetes is expected to produce a corresponding increase in the burden of tuberculosis. Hence, it 
poses	a	threat	to	the	attainment	of	the	Millennium	Development	Goals	on	tuberculosis	(Goldhaber-
Fiebert	et	al		2011).
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Figure 4. Percentage of tuberculosis cases attributable to diabetes (20-79 years), 
2011.
Source: IDF Diabetes Atlas, 2011    http://www.idf.org/diabetesatlas
THE SOUTH AFRICAN FIGURES FOR DIABETES
The	estimated	prevalence	of	diabetes	in	South	Africa	in	2012	was	7.0%.	Although	it	is	not	amongst	
the highest in the world, the translation in terms of total number of diabetics results in a enormous 
amount when predicted as to be double in a decade.
 
Although the prevalence of diabetes in South Africa is not amongst the highest in the African region, 
in terms of total people living with diabetes, South Africa, at 1.9 million, is only second to Nigeria 
with	3	million;	this	effect	 is	 largely	due	to	the	population	size	(International	Diabetes	Federation	
2011).	Similar	translation	is	required	when	analysing	the	South	African	reports	on	prevalences	of	
risk	factors	and	diabetes	death	rates	shown	in	figure	5.
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Figure 5. Summary statistics for non- communicable diseases in SOUTH AFRICA (2011) 
as compared to the current leading causes of death.
Source: World Health Organization 2011- NCD Country Profiles.
Summary of the South African estimates for diabetes mellitus (DM) and Impaired glucose 
tolerance (IGT), (20-79 years).
2011 2030
TOTAL POPULATION 30 111 820 35 422 200
PREVALENCE OF DM 6.5% 7.2%
TOTAL PEOPLE LIVING WITH DM 1 946 600 2 548 100
PREVALENCE OF IGT 7.0% 8.0%
TOTAL PEOPLE LIVING WITH IGT 2 113 100 2 846 500
DEATHS ATTRIBUTED TO DM 3%
TOTAL DEATHS ATTRIBUTED TO DM 63 061
TOTAL UNDIAGNOSED DIABETICS 1 557 300
DM-RELATED MEAN EXPENDITURE
PER PERSON WITH DIABETES
695 U.S.D
 
Source: Source: IDF Diabetes Atlas, 2011, 5th Ed    http://www.idf.org/diabetesatlas
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CONSEQUENCES OF THE BURDEN OF DIABETES
SOCIOECONOMIC CONSEQUENCES 
The human and social issues
Diabetes is a global epidemic that results in devastating consequences to the society, the family 
and the diabetic individuals. In terms of society, the diabetes epidemic implies millions of people 
living with this chronic disease, with the associated costs of therapy, which become higher in the 
presence	of	associated	acute	and	chronic	complications	(Anderson	et	al	1997).	The	commonly	faced	
economic	disability,	death	and	related	financial	distress	secondary	to	diabetes,	can	cause	quite	a	
social drama at the level of the family. In terms of the person, the quality of life of diabetic patients 
in	general	is	just	not	as	satisfactory	as	for	individuals	without	chronic	diseases	(Trief	et	al	1998).	
In addition, increasing levels of deterioration of their quality of life arrive with their adaptation 
to	 dietary	 modifications,	 treatment	 choices	 (insulin	 injection	 versus	 oral	 hypoglycaemic	 drugs),	
glycaemic	control	and	also	with	the	presence	of	associated	complications	(Rubin	and	Peyrot	1999).	
Rose	et	al	(1998)	described	that	the	whole	self-perception	of	quality	of	life	by	these	patients	changes	
as ‘a function dependent on psychosocial factors such as health and cultural beliefs, social support, 
coping strategies and personality traits’.
The Economic issues
Dall	et	al	(2010)	highlight	two	important	aspects	in	the	economic	burden	of	diabetes.	These	can	be	
divided into direct and indirect cost. The direct cost is the cost attributable to health care services 
and, the indirect cost is due to productivity loss associated with diabetes. The direct health care 
costs for diabetes include the costs for ambulatory management, for treating the diabetic medical 
emergencies and for the in-ward hospital admissions. On the other hand, the indirect costs are the 
losses affecting the economy by reducing the productivity arise from increased rates of absenteeism, 
reduced productivity whilst at work, disability that prevents work and premature death. The increased 
financial	burden	of	diabetes	affects	the	national	economies	by	“competing”	for	funds	with	the	other	
national	priorities	(Dall	et	al	2010).
The estimate of the economic burden for the 17.5 million people living with diabetes in the U.S.A 
in	2007	 is	$174.4	billion,	with	an	estimate	of	$159.5	corresponding	to	type	2	diabetes.		(Dall	et	
al	2010).	For	2012,	the	American	Diabetes	Association	(2013b)	reported	a	41%	increase	over	the	
initial	estimate,	making	a	total	estimate	of	$245	billion.	
The instrumental models used to estimate the epidemiological and economic burden of diabetes 
require	accurate	records	to	derive	reliable	current	and	prospected	figures	that	actually	correspond	
to the national particularities and guide their strategic plans.
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Figure 5. Total healthcare expenditures due to diabetes (20-79 years) (USD), R=2*, 
2011:
Source: IDF Diabetes Atlas, 2011    http://www.idf.org/diabetesatlas
The	figure	reflects	the	potential	 influences	of	the	socio-economic	development,	type	of	economy	
and national internal product as a source of disparities in the healthcare expenditures for diabetes 
for the different regions. 
According	to	the	International	Diabetes	Federation	(International	Diabetes	Federation	2011):
The	North	America	and	Caribbean	Region	spent	an	estimated	USD	223	billion	or	48%	of	the	•	
global	healthcare	expenditures	for	diabetes	in	2011.		
The Europe Region spent about half that amount at USD 130 billion. These two regions combined •	
had	the	highest	expenditures	due	to	diabetes	in	2011.		
In	 comparison,	 the	Western	Pacific	Region	 spent	only	USD	72	billion	on	diabetes	healthcare	•	
despite having the largest number of people with diabetes. 
The South and Central America and Middle East and North Africa Regions each spent less than •	
5% of the global total on healthcare expenditures due to diabetes, while,
The	Southeast	Asia	and	Africa	Regions	spent	less	than	1%	in	2011.•	
The	basic	data	in	figure	5	is	based	on	extrapolations	and	estimates	calculated	from	the	total	healthcare	
expenditures. The actual individual cost of care per diabetic patient per year in South Africa is not 
available.
IMPLICATIONS OF THE BURDEN OF DIABETES FOR HEALTH PLANNING
There are two important perspectives of the socioeconomic impact of the burden of diabetes. One 
is regarding the implications arising from the projected growing burden of diabetes and the other 
relates to implications for the people already living with diabetes.
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DIABETES PREVENTION AS STRATEGY
The value of community-based research and community-based preventive 
interventions:
The socioeconomic impact implied by the projected burden of diabetes calls for community-based 
health interventions addressed to prevent the further increase of the total number of people living 
with	diabetes.		Diabetes	prevention	as	a	strategy	encompasses,	in	the	first	place,	the	identification	
of the dominant pattern of contributing risk factors for diabetes in each community. Although 
prevention strategies also involve added healthcare costs, experiences from some intervention trials 
have demonstrated that investing in preventative programs is likely to reduce the transit from pre-
diabetic status into diabetes, which in turn decreases the cost of managing diabetes mellitus and 
its	complications	(WHO	1994).		However,	there	are	no	off-the-shelf	interventions	to	be	effectively	
extrapolated from other studies as the impact cannot be the same in different settings. Thus, the 
planning process for community interventions must rely on the availability of data representative 
of the risk expressed in each community. For example, in the case of South Africa, we have seen 
the statistical evidence of the different prevalences across population groups, geographic areas, 
sociocultural background, etc. Thus, a unique prevention plan is not likely to improve cost-effectively 
the	situation	in	the	whole	country	(Unwin	et	al	2001).
For the selection of possible strategies, before embarking on the planning, some questions that 
need answers are:  
Are the projections for the burden of diabetes in this community accurate? •	
What	is	the	actual	number	of	people	living	with	diabetes,	in	this	community?	•	
Do they even know they have diabetes? •	
Which	risk	factors	are	paramount	in	our	community?	Are	they	modifiable?	•	
Would	the	expected	impact	of	such	intervention	justify	the	cost	of	its	implementation?		•	
Such questions are not easy to answer. The answers need a body of evidence extracted from 
community-based research. Academic institutions play a key role in obtaining these epidemiological 
information	from	their	communities	(Unwin	et	al	2001;	Mbanya	2010).	
The relevant population data generated from community studies establish the grounds on which the 
higher education institutions and the community recommend and provide supportive expertise to 
health policy makers and health administrators to oversee the strategic and cost-effective design of 
the	preventive	interventions	(Zimmet	1999).	
The estimation of the cost-effectiveness of diabetes prevention strategies regarding costs, quality 
of life, and health outcomes is necessary to deliver a cost analysis that goes beyond total costs but 
rather	defines	costs	translated	into	improved	quality	of	life.	One	of	the	recommended	units	is	the	cost	
per	quality-adjusted	life-year	gained	over	a	lifetime	(Herman	et	al	2005).		Additionally,	the	higher	
cost-effectiveness of the prevention programs can be attained by using an integrated approach, 
which is not only dealing with the prevention of diabetes but also, at the same time, targets other 
coexisting risk factors such as those for cardiovascular diseases. The integrated approach allows the 
sharing	of	common	resources	and	avoids	the	duplication	of	programs	(Simmons,	Griffin	&	Wareham	
2007;	Alberti,	Zimmet	&	Shaw	2007).
The collaborative participations by the three parties: academy, community and health authority then 
continues the cycle during the implementation and the evaluation of the interventions.
Numerous	interventions	for	the	prevention	and	control	of	diabetes	have	proven	to	be	beneficial	in	
different	settings	(Jamison	et	al,	2006,	Chap.	5,	p.594).
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Examples of typical diabetes interventions, at different stages, and their reported 
benefits:
  
STRATEGY BENEFIT
COST EFFECTIVENESS RA-
TIO (US$/ quality-adjusted 
life year)
Preventing diabetes
Lifestyle interventions for pre-
venting	type	2	diabetes	
Reduction of 35% - 58% in inci-
dence among people at high risk
1,100	(Diabetes	Prevention	Pro-
gram Research Group forthcom-
ing)
Metformin	for	preventing	type	2	
diabetes
Reduction	of	25%	-	31%	in	inci-
dence among people at high risk
31,200	(Diabetes	Prevention	
Program Research Group forth-
coming)
Screening for diabetes
Screening	for	type	2	diabetes	in	
general population
Reduction	of	25	%	in	microvas-
cular disease
73,500	(CDC	Diabetes	Cost-Ef-
fectiveness	Study	Group	1998)
Treating diabetes and its complications
Annual screening for microalbu-
minuria
Reduction of 50% in nephropa-
thy using ACE inhibitors for iden-
tified	cases
47,400	(Klonoff	and	Schwartz	
2000)
Annual eye examinations Reduction of 60% to 70% in se-
rious vision loss
6,000	(Klonoff	and	Schwartz	
2000;	Vijan,	Hofer,	and	Hayward	
2000)
 (Jamison et al, 2006, Chap. 5, p.594)
CONTROL OF THE CURRENT BURDEN OF DIABETES
Targeting specific standards of care for diabetes 
Improving standards of care for diabetes to improve glycaemic control and prevent the development 
of complications can reduce the socioeconomic impact of the current burden of diabetes. It can do 
this by decreasing associated morbidity, diabetic emergencies, related disabilities and death as well 
as improving the quality of life of the people living with diabetes.
This aspect has a stronger public healthcare perspective as it is more related to management 
interventions addressed to patients who already live with the disease. However, as it happens with 
the prevention, strategies for controlling the current burden of diabetes, also need research inputs. 
to show the directions to be strengthened according to the prevalences of complications in the 
diabetic population and challenges in their management.  Research is also necessary to evaluate the 
effectiveness of the implemented management interventions. 
Although the supportive reports on this aspect are more likely to emerge from healthcare centres 
rather than from community studies, the collaborative and integrated strategy recommended in the 
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prevention	is	also	a	powerful	cost-effective	method	for	the	control	of	the	disease	(Unwin	et	al	2001;	
Mbanya	2010;	Simmons,	Griffin	&	Wareham	2007;	Alberti,	Zimmet	&	Shaw	2007).	
It is necessary to emphasize the need to publish the results and statistics of the conducted research 
in	scientifically	recognized	sources	to	be	shared	with	the	international	scientific	community	and	with	
the international diabetes organizations, to provide updated data  to be used when calculating new 
estimates and their impact of the various local, national and regional interventions on the burden 
of diabetes.
Some areas requiring further research attention in South Africa:
The current epidemiological burden of diabetes to see how much it has actually increased •	
(validation	of	estimates)
The pattern of prevalence of diabetes for rural and urban populations•	
The current prevalence of type 1 diabetes •	
The	current	financial	burden	of	diabetes•	
The current prevalence of diabetic complications•	
In addition to the above areas, the following arise from the experiences in the former 
Transkei:
The prevalence of undiagnosed diabetes•	
The effect of obesity as a risk factor for diabetes in the community•	
The complete model of nutritional assessment and physical activity using validated protocols for •	
both the general and the diabetic population.
The progressive evaluation of the quality of diabetic care provided•	
The genetic linkages related to the family history  •	
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CONCLUSIONS
The	emerging	epidemic	of	type	2	diabetes	is	a	global	problem	requiring	global	attention	and	urgent	
action.
The	predicted	progression	of	the	type	2	diabetes	epidemic	in	South	Africa	constitutes	a	threat	to	
public health and the economy that needs the development of timely cost-effective interventions, 
however, further urgent community research is vital to validate the current estimates.
 
The control of the burden of diabetes in South Africa requires collaborative and coordinated action 
from different sectors at all levels; the three more prominent probably are the Department of Health, 
the Academic Institutions and Communities. Some strategic tasks to be addressed are:
The development and implementation of cost-effective health strategies to provide integrated & •	
coordinated care in response to the needs of the community and adapted for the administrative 
structure in place. 
The development of human resources capacity to provide appropriate multidisciplinary support •	
to patients and healthcare programs at all levels.
The	 intensification	 of	 community	 health	 education	 to	 foster	 healthier	 lifestyles,	 improve	 the	•	
patient’s participation in self-control and self-monitoring of diabetes, community ownership of 
health programs, and alleviation of the shortage of staff.
Academic institutions to provide the research expertise needed from all different perspectives of •	
the	problem	(healthcare,	epidemiology,	economic,	cultural,	educational,	nutritional,	psychological,	
etc.)	 by	 using	 their	 research	 capacity	 and	 gaining	 access	 to	 research	 resources	 from	 local	
government and from external funding agencies. Furthermore, academic institutions must 
address any needed curricular changes to ensure that the outgoing professionals are relevant to 
the needs of the communities.
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